CER budgets heading up in '12

Share this article:

More than half of drug companies plan to increase spending for market-access activities in 2012, including comparative effectiveness research (CER), according to a report from Cutting Edge Information.

Responding to payer demands for outcomes, virtually all drug research companies expect to at least maintain spend across most market-access categories, the benchmarking study showed.

Growth areas include health economics and outcomes research (64% of firms plan to increase funding), as well as patient-reported-outcomes activities, pegged by 57% of respondents for more spend, and CER, which half of firms anticipate upping their spend for.

Across all market access activities studied, pricing teams' budgets will largely remain the same. And according to the study, 73% of companies will hold their pricing budgets steady next year.

Cutting Edge talked to 20 companies for its study, said Elio Evangelista, director of research for the firm.
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"